London South East | The UK's favourite investor portal.

those links didn't work - lol

go to the undernoted and you will find both there

https://www.cambridgecommodities.com/news.htm

product line up from April 28th lists

We're back at Vitafoods from 10-12 May on stand I39! We will be showcasing a variety of exciting new products and highlighting key trends in the industry.

Here is an overview of our latest product innovations:
Weight management

Glucomannan Puffs
Sea Salt & Balsamic Vinegar – (P16940)
Thai Sweet Chilli – (P16941)
Vegan Cheeze – (P16942)
BBQ – (P16943)
Keto All in One (P15425)
Keto Digestive Greens (P15426)
Keto Collagen and Salts (P15493)

mol

Extract

Anyone living with psoriasis (hey, Kim Kardashian and Cara Delevingne) will know how itchy and sore it can be, but the well-known physical symptoms are just a scratch on the surface compared to the full reality of living with the condition. Its chronic nature can seriously affect self-esteem and confidence due to the patches of dry skin it causes, which can often be very red and cracked.

Dr Clare Morrison, GP and Medical Advisor at Medexpress, says: “Psoriasis is a skin condition that causes red, flakey, crusty patches of skin covered with silvery scales. It's often worse on the elbows, knees, scalp and back but can occur anywhere.

“In this condition, skin cells build up too thickly instead of being shed normally.” Skin cells are normally created and replaced every 3-4 weeks, but in those with psoriasis, this process only takes 3-7 days. The result is the build-up of cells that we recognise as psoriasis.

What is the best treatment for psoriasis?

Like most things in life, there's no cure-all treatment, but there are certain things you can do to soothe symptoms.
Psoriasis creams and ointments

Dr Claire suggests creams and ointments that include coal tar, steroids, vitamin D analogues such as calcipotriol, retinoids, salicylic acid, and moisturisers.

Ultraviolet light

Dr Claire says that after "sensitising the skin with psoralen", ultraviolet light can be administered by a registered dermatologist to alleviate sensitivity.

Then there's the new microbiome-based treatment from AxisBiotix, a blended gut-skin health supplement composed of natural bacteria that has been specifically designed to improve skin health. While still a relatively new treatment, results have been extremely promising. A study of 265 people suffering from mild to moderate psoriasis,
74% of participants reported that they were less itchy, 73% less red, 71% less irritable, 64% less flaky patches – with most of the changes reaching peak effectiveness within two weeks of taking AxisBiotix.

Other treatments include oral immunosuppressants such as methotrexate, but Dr Claire advises that this isn't suitable for women who may become pregnant and can cause problems such as liver disease.

https://www.glamourmagazine.co.uk/gallery/psoriasis-treatment

mol

mol

Just thought I would review this again tonight - at a loose end at moment - lol

RNS 12 February 2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its wholly-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a licencing agreement with Granja Pocha S.A. ("Granja Pocha") for the inclusion of ProBiotix's patented probiotic strain LPLDL® into a functional yogurt product in Uruguay, South America.

Under the terms of the agreement, SACCO S.r.l., which helped develop the yogurt formulation, will supply ProBiotix's cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LPLDL®, under a non-exclusive licence to Granja Pocha for inclusion into fermented milk products, such as yogurts, in Uruguay, with the aim of maximising the financial return for both Granja Pocha and ProBiotix. There are no minimum sales targets in the licencing agreement.

Granja Pocha, was founded in 1980 in the main dairy basin of the Río de la Plata, Juan Lacaze, department of Colonia, Uruguay. Since 2013, they have sold products under the Colonial brand, including dulce de leche, cheeses, and yogurts. Granja Pocha describe themselves as having become one of Uruguay's largest and most respected dairy producers over the years.

Steve Prescott, CEO of ProBiotix, commented: "We are pleased to announce this agreement with Granja Pocha, which will expand LPLDL®'s presence into South America and extends its use into dairy products. Granja Pocha was chosen as our partner to create a functional yogurt containing LPLDL® because of their technical expertise in dairy, track record of successfully launching new products, and extensive knowledge of the local market. The work carried out by Granja Pocha is a significant milestone as it extends the use of LPLDL® into functional foods, in this case dairy, which may be replicated in other territories. Functional foods like this yogurt containing ProBiotix's LPLDL® provide a unique format for customer to receive the cholesterol reducing benefits of LPLDL® and capitalises on a growing industry trend towards functional foods."

Write up here

https://www.nutraingredients-latam.com/Article/2020/03/12/OptiBiotix-and-Granja-Pocha-develop-functional-probiotic-yogurt-for-Uruguay-market#

Steve appointed 1 July 2019

all looking good - but

Steve's appointment terminated 29 May 2020 (just over 3 months from RNS)

part 2 to follow

RNS 8 Oct 2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces the appointment of Aneta Zlotkowska as Head of Quality & Operations.
Aneta holds a CIPS Diploma in Procurement and Supply Chain Management and has completed HACCP and BRC Third Party Auditor courses by the BRC Academy.

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "Given OptiBiotix's rapid international expansion with the announcements of various distribution and manufacturing agreements for SlimBiome®, OptiBiome® and WellBiome® as well as commercial launches of finished products containing OptiBiotix's technology in the UK (RNS: 7 January 2020) and the USA & Canada (RNS: 4 May 2020), we feel the need to appoint a full-time employee with the relevant skillset to manage and lead OptiBiotix's quality management system and operations.

"Aneta will join the Company on 1 January 2021 and will work towards ensuring timely deliveries of high-quality ingredients to OptiBiotix's partners around the world. Moreover, Aneta is tasked with attaining a BRC certification for OptiBiotix Ltd.

So Aneta specifically tasked with BRC

13 April 2021

Bringing more than 25 years of business development experience to the role, Kamminga joins OptiBiotix as CEO from his prior role at KD Pharma Group
OptiBiotix Health has announced the appointment of René Kamminga as CEO of its wholly owned subsidiary, OptiBiotix.
Following the appointment, Dr Frederic Narbel will move from his position as director of the OptiBiotix board and managing director of the functional fibres division to a more strategic role as Non-Executive Director of OptiBiotix in June. “I would like to thank Fred for his ongoing contribution to OptiBiotix,” said O’Hara. “He has been instrumental to the commercial success of SlimBiome with many of our partners around the world. The leadership team and board look forward to him taking a more strategic role in the business later this year.”

Fred's strategic role (as i have previously noted) didn't last long - as per companies house filing and not rnsed by our company - so much for Stephen's comment in RNS

26 May 2021
Date of termination: 26/05/2021
Name: MR FREDERIC NARBEL

Then good news

RNS 5 Jan 2022

"René Kamminga, CEO of OptiBiotix Limited, commented: "We are very pleased to announce our BRC accreditation which supports our commercial strategy of selling final product solutions to partners in the retail channel containing our science backed pro and prebiotic ingredients. I am particularly proud of our team which achieved this accreditation in a relatively short period of time."

Aneta Zlotkowska had already left in Dec 2021 - mind she had achieved that which she was tasked with albeit originally appointed as a full time employee

Many thanks Aneta

mol

summary - at least my take - re pbx shares in issue

53,533,333 opti
11,904,762 placing and subscription ( we now know seneca partners 8,025,450)
9,761,904 CLNotes
48,847,611 Nominee (opti div in specie which includes concert party)

equals

124,047,610
less 2,380,944 being opti 250,000 CLN's at .105p (50% discount)
equals
121,666,666 on admission

By way of reminder re Convertible Loan notes

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that further to the announcement on 24 September 2018 regarding the formation of the Company's wholly owned subsidiary ProBiotix Health Limited ("ProBiotix"), ProBiotix has raised £1.025 million of capital through the issue of convertible loan notes ("CLN").

The proceeds from the issue of CLNs will be used to provide funding for a potential initial public offering of ProBiotix. This is in line with OptiBiotix's strategy announced on 5 July 2016 to form separate divisions, which could in due course become separate legal entities with the potential for a separate public listing. OptiBiotix's strategy is based on its belief that the diversity of IP and commercial relationships across its four divisions reduces shareholder risk whilst offering multiple opportunities for value enhancement.

OptiBiotix plc has subscribed for £250,000 of CLNs. Steve O'Hara, a director of the Company, has subscribed for £25,000 and certain close family members of Mr. O'Hara have subscribed for £265,000. In addition, Per Rehné, a director of the Company, has subscribed for £25,000. The remaining subscribers include two institutional investors and two industry partners.

The CLNs can be converted at a fifty per cent. discount to the issue price of ProBiotix shares in the event of an IPO. The CLNs carry an interest rate of 3% per annum above the Bank of England Base Rate.
As of 14 December 2018, Steve O'Hara has an interest in 10,103,029 ordinary shares in the Company, representing 11.9 per cent. of the Company's issued share capital and has an interest in a further 6,099,135 ordinary shares under option.

so basically placing and subscription not locked in = 9.78% (albeit some of the CLN converted shares will also not be locked in)

if we take off seneca then c4-5% not locked in though i cannot see any of the placing/subscription shares trading any time soon - just leaves some of the CLN converted shares then - perhaps Per selling some?

mol

summary - at least my take - re pbx shares in issue

53,533,333 opti
11,904,762 placing and subscription ( we now know seneca partners 8,025,450)
9,761,904 CLNotes
48,847,611 Nominee (opti div in specie which includes concert party)

equals

124,047,610
less 2,380,944 being opti 250,000 CLN's at .105p (50% discount)
equals
121,666,666 on admission

By way of reminder re Convertible Loan notes

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that further to the announcement on 24 September 2018 regarding the formation of the Company's wholly owned subsidiary ProBiotix Health Limited ("ProBiotix"), ProBiotix has raised £1.025 million of capital through the issue of convertible loan notes ("CLN").

The proceeds from the issue of CLNs will be used to provide funding for a potential initial public offering of ProBiotix. This is in line with OptiBiotix's strategy announced on 5 July 2016 to form separate divisions, which could in due course become separate legal entities with the potential for a separate public listing. OptiBiotix's strategy is based on its belief that the diversity of IP and commercial relationships across its four divisions reduces shareholder risk whilst offering multiple opportunities for value enhancement.

OptiBiotix plc has subscribed for £250,000 of CLNs. Steve O'Hara, a director of the Company, has subscribed for £25,000 and certain close family members of Mr. O'Hara have subscribed for £265,000. In addition, Per Rehné, a director of the Company, has subscribed for £25,000. The remaining subscribers include two institutional investors and two industry partners.

The CLNs can be converted at a fifty per cent. discount to the issue price of ProBiotix shares in the event of an IPO. The CLNs carry an interest rate of 3% per annum above the Bank of England Base Rate.
As of 14 December 2018, Steve O'Hara has an interest in 10,103,029 ordinary shares in the Company, representing 11.9 per cent. of the Company's issued share capital and has an interest in a further 6,099,135 ordinary shares under option.

mol

by way of info posted this on pbx board this evening in reply to nick et al

Evening all

From admission document

Lock-In Agreements” the lock-in agreements between the Company, Peterhouse and each of the Locked-In Parties (respectively), further details of which are set out in paragraph 9.4 of Part VII of this Document

“Locked-In Directors” those Directors who hold Ordinary Shares or who will acquire or receive Ordinary Shares during the Lock-In Period (being all of the Directors with the exception of Marco Caspani)

“Lock-In Period” in the case of the Locked-In Directors and OptiBiotix, the period of 12 months following Admission, and, in the case of the Nominee, the period of 9 months following Admission.

On 31 March 2022, the Locked-In Directors and OptiBiotix entered into lock-in agreements with the Company and Peterhouse pursuant to which they have agreed to be subject to a twelve-month lock-in period.

On 31 March 2022, the Nominee entered into a lock-in agreement with the Company and Peterhouse pursuant to which it has agreed to be subject to a nine-month lock-in period. During the Lock-In Period, subject to certain exceptions, none of the Locked-In Parties may issue, offer, sell or contract to sell, or otherwise dispose of any Ordinary Shares or enter into any transaction with the same economic effect as the foregoing (each a ‘‘Disposal’’).

OptiBiotix has, however, agreed with Peterhouse that it will make Ordinary Shares available for sale within that twelve-month period if such a Disposal is required to maintain an orderly market in the Ordinary Shares. In addition, the Locked-In Parties, other than the Nominee, have also agreed that any Disposal made by them in the subsequent twelve-month period will be undertaken, save in certain circumstances, only following Peterhouse’s agreement and if brokered through the Company’s broker.

Following Admission, certain Shareholders will be presumed to be acting in concert for the purposes of the City Code in relation to their shareholdings in the Company, namely (1) OptiBiotix; (2) Stephen O’Hara; (3) John O’Hara and (4) Thomas O’Hara (the “OptiBiotix Concert Party”).

The members of the OptiBiotix Concert Party are deemed to be acting in concert by virtue of their family relationships and positions as directors and/or shareholders of OptiBiotix.

On Admission, the OptiBiotix Concert Party will between them be interested in 63,246,684 Ordinary Shares, representing 51.98 per cent of the Issued Share Capital and will have Options over a further 3,000,000 Ordinary Shares.

It was all set out in admission document - albeit not made public until after the event and placing achieved - largely seneca

mol

Evening all
From admission document

Lock-In Agreements” the lock-in agreements between the Company, Peterhouse and each of the Locked-In Parties (respectively), further details of which are set out in paragraph 9.4 of Part VII of this Document

“Locked-In Directors” those Directors who hold Ordinary Shares or who will acquire or receive Ordinary Shares during the Lock-In Period (being all of the Directors with the exception of Marco Caspani)

“Lock-In Period” in the case of the Locked-In Directors and OptiBiotix, the period of 12 months following Admission, and, in the case of the Nominee, the period of 9 months following Admission.

On 31 March 2022, the Locked-In Directors and OptiBiotix entered into lock-in agreements with the Company and Peterhouse pursuant to which they have agreed to be subject to a twelve-month lock-in period.

On 31 March 2022, the Nominee entered into a lock-in agreement with the Company and Peterhouse pursuant to which it has agreed to be subject to a nine-month lock-in period. During the Lock-In Period, subject to certain exceptions, none of the Locked-In Parties may issue, offer, sell or contract to sell, or otherwise dispose of any Ordinary Shares or enter into any transaction with the same economic effect as the foregoing (each a ‘‘Disposal’’).

OptiBiotix has, however, agreed with Peterhouse that it will make Ordinary Shares available for sale within that twelve-month period if such a Disposal is required to maintain an orderly market in the Ordinary Shares. In addition, the Locked-In Parties, other than the Nominee, have also agreed that any Disposal made by them in the subsequent twelve-month period will be undertaken, save in certain circumstances, only following Peterhouse’s agreement and if brokered through the Company’s broker.

Following Admission, certain Shareholders will be presumed to be acting in concert for the purposes of the City Code in relation to their shareholdings in the Company, namely (1) OptiBiotix; (2) Stephen O’Hara; (3) John O’Hara and (4) Thomas O’Hara (the “OptiBiotix Concert Party”).

The members of the OptiBiotix Concert Party are deemed to be acting in concert by virtue of their family relationships and positions as directors and/or shareholders of OptiBiotix.

On Admission, the OptiBiotix Concert Party will between them be interested in 63,246,684 Ordinary Shares, representing 51.98 per cent of the Issued Share Capital and will have Options over a further 3,000,000 Ordinary Shares.

It was all set out in admission document - albeit not made public until after the event and placing achieved - largely seneca

mol

and is likely to witness significant growth due to growing consumer awareness regarding the availability of digestive health products. Also, the abundance of specialty health products, real-time product delivery, high prevalence of obesity, along with developments & technological advancements in health products supported by the regional government, will offer lucrative opportunities for market expansion.

Asia- Pacific region is estimated to register the fastest growth rate of around 9.5% through 2027 due to a rise in health awareness among the populace and growing disposable income in the region. China, India, and Japan are among the largest regional markets for digestive health products with the presence of a large consumer base.

The key players operating in the digestive health products market include Chr. Hansen Holding, Nestle SA, E. I. DuPont Nemours and Company, Yakult Honsha Co. Ltd., and Danone SA. Other few dominant players in the digestive health products market are Cargill Inc., Mondelez International Inc., Arla Foods Inc., General Mills and PepsiCo Inc. These industry players are adopting several strategies such as acquisitions, mergers, collaborations, new product development, and capacity expansion, thereby supporting the overall growth of the market. Moreover, rising investments by the key industry players for the R&D activities will further bolster market growth over the analysis period.

On 6th August 2020, OptiBiotix Health announced the extension of the deal with global partners for the distribution of its fiber, mineral lend products, and probiotic supplements. The extension mainly pertains to WellBiome and CholBiome, which address digestive and cardiovascular health, respectively, and are available in the U.S., Germany, Australian and Asian markets.

On 1st September 2020, GT Living Foods, the makers of GT’s Synergy, the world’s leading Kombucha brand, announced foraying into the functional beverage landscape with GT’s Aqua Kefir, which is a pre- and post-workout hydration drink.

The above report's publication date is June 2022 and whilst I have no intention of buying same it was good to note we got a mention in their pre-publication spiel

mol

Latest Share Chat

Member Info for mol42

Followers

Following

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution (Last 30 Days)

Activity Log (Last 30 Days)

Latest Share Chat

Member Info for mol42

Followers

Following

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution (Last 30 Days)

Activity Log (Last 30 Days)

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending